Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Extended follow-up of in vivo BCMA CAR-T therapy in RRMM shows 100% ORR (2/4 CR, 2/4 PR) but median PFS only 4 mos, OS 5.5-10.9 mos, 3/4 relapsed & had extramedullary disease; authors conclude need to extend persistence.”
Title: Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Authors: Jia Xu, Lin Liu, Wei Xie, Liman Su, Weijiayi Wang, Chenggong Li, Qiaolin Liu, Yun Kang, Yinqiang Zhang, Wenjing Luo, Zhongpei Huang, Chun Zhang, Chunyan Sun, Yu Hu, Heng Mei
You can read the full article on Nature Medicine.
You can find other articles featuring Robert Orlowski on OncoDaily.
